Randomized Phase III Study 306
Gregory L. Krauss,Joan Serratosa,Vicente Villanueva,Milda Endzinienė,Zhen Hong,Jacqueline French,Yang Huang,David Squillacote,Hannah Edwards,Jin Zhu,Antonio Laurenza,Samuel F. Berkovic,Wendyl D’Souza,Terence J. O’Brien,Udaya Seneviratne,Martin Robinson,Plamen Bozinov,Ivan Milanov,Еkaterina Titianova,Zahari Zahariev,Liwen Wu,Xuefeng Wang,Dong Zhou,Jindriska Buresova,Jan Hadač,Petr Marusič,Hana Ošlejšková,Sulev Haldre,Ain Pajos,Valentin Sander,Inga Talvik,Stephan Arnold,A. Hufnagel,Frank Kerling,Holger Lerche,Soheyl Noachtar,Felix Rosenow,Joachim Springub,Bernhard J. Steinhoff,Konrad J. Werhahn,Raymond Tak Fai Cheung,Patrick Kwan,Ping Wing Ng,John S.D. Chan,Attila Balogh,István Kondákor,Magdolna Neuwirth,Péter Rajna,György Rásonyi,Joy Desai,Sudhir Kothari,Sita Sattaluri,Bhawna Sharma,Nandan Yardi,J. M. K. Murthy,Manmohan Mehndiratta,Kolichana Venkateshwaralu,Silvana Franceschetti,Guntis Karelis,Guntis Rozentals,Baiba Uskane,Rūta Mameniškienė,Irena Virketiene,Zariah Abdul Aziz,Kheng‐Seang Lim,Mei‐Ling Sharon Tai,Maria Epifania Collantes,Katerina Tanya P. Gosiengfiao,Anna Członkowska,Wiesław Drozdowski,Waldemar Fryze,Jacek Gawłowicz,Maria Mazurkiewicz‐Bełdzińska,E Motta,Carla Bentes,Luı́s Cunha,Gabriela Liberato de Sousa,J. M. Lopes Lima,Ioana Mı̂ndruță,Dezso Nagy,Sanda Maria Nica,Elena Belousova,Vladimir V. Kalinin,Е. В. Левитина,Н. Б. Перунова,Н. В. Пизова,И. Е. Повереннова,П. Н. Власов,Dragoslav Sokić,Ksenija Božić,N. Jović,Žarko Martinović,Mirjana Spasić,Seung Bong Hong,Joong Koo Kang,Sang Ho Kim,Sung Eun Kim,Byung-In Lee,Sang Kun Lee,Yong Won Cho,Francisco José García Hernández,Juan Luís Becerra,A. Escartin Siquier,Irene García Morales,J López-Trigo,Antonio Valls Santasusana,Jean‐Claude Alvarez,Tayard Desudchit,Surachai Likasitwattanakul,Charcrin Nabangchang,Somsak Tiamkao,Nantaporn Tiyapun,Jing‐Jane Tsai,Pei‐Fang Hsieh,Yu‐Lung Tseng,Yuli Wu,Sergii Kharchuk,Tetyana Litovchenko,I. S. Lutskyy,Iryna Makedonska,Viktoria Martyniuk,L.B. Maryenko,Volodymyr Smolanka,Petro Voloshyn,S.К. Yevtushenko
DOI: https://doi.org/10.1212/wnl.0b013e318254473a
IF: 9.9
2012-01-01
Neurology
Abstract:To evaluate the efficacy and safety of perampanel 2, 4, and 8 mg/day added to 1-3 concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures.During this double-blind, placebo-controlled trial, patients with persisting seizures on 1-3 AEDs were randomized to perampanel 2, 4, and 8 mg/day or placebo following a 6-week baseline phase. Perampanel was titrated weekly by 2 mg/day and maintained at the dose achieved for 13 weeks. Primary endpoints were median percent change in seizure frequency and 50% responder rate. Analysis of covariance was performed on all treated patients with any seizure data (recorded in daily diaries) in the double-blind phase.A total of 706 patients were randomized and received trial medication; 623 completed the trial. Median percent change in seizure frequency-the primary efficacy endpoint-was -10.7%, -13.6%, -23.3%, and -30.8% for placebo, perampanel 2, 4, and 8 mg/day, respectively. The difference from placebo was statistically significant for perampanel 4 mg/day (p = 0.0026) and 8 mg/day (p < 0.0001). The corresponding 50% responder rates were 17.9%, 20.6%, 28.5%, and 34.9%. The difference from placebo was statistically significant for perampanel 4 mg/day (p = 0.0132) and 8 mg/day (p = 0.0003). An apparent dose response was suggested for dizziness, which was the most frequent treatment-emergent adverse event.This trial demonstrated that adjunctive perampanel effectively reduced seizure frequency and possessed a favorable tolerability profile in patients ≥12 years with partial-onset seizures (with or without secondary generalization), with a minimum effective dose of 4 mg/day.This study provides Class I evidence that 4 and 8 mg/day doses of adjunctive perampanel are effective and tolerated in reducing partial-onset seizures.